Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAGE-1161-169 peptide vaccine
- Development stage
- Unknown
- Lead developer
- Fred Hutch
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Intramuscular
01
Overview
MAGE-1161-169 peptide vaccine is a personalized peptide-based cancer vaccine intended for immunotherapy in patients with melanoma. It contains synthetic peptide sequences corresponding to the MAGE-1161-169 region, which is a fragment of a melanoma antigen gene (MAGE) commonly expressed in melanoma tumors. This vaccine is designed to stimulate an antigen-specific immune response—primarily cytotoxic T lymphocyte (CTL) activation—against tumor cells that present the MAGE peptide on their surface. The mechanism involves presentation of the MAGE-1161-169 peptide by major histocompatibility complex (MHC) molecules, resulting in immune recognition and destruction of melanoma cells[8]. Peptide vaccines such as this are typically used in combination with adjuvants (e.g., poly ICLC) and immune checkpoint inhibitors (e.g., nivolumab) to enhance anti-tumor immunity[1][2]. MAGE-1161-169 is an example of personalized neoantigen vaccine approaches tailored to individual tumor profiles in advanced melanoma.
- Brand names
- MAGE-1161-169 peptide vaccineMAGE1161-169 peptide vaccineMAGE 1161-169 peptide vaccine
- Other names
- MAGE-1161-169 peptide vaccineMAGE1161-169 peptide vaccineMAGE 1161-169 peptide vaccine
02
Targets
pMHC (Peptide-MHC complex family)MAGE (Melanoma-associated antigen family)
Beyond the preview
Go deeper on MAGE-1161-169 peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAGE-1161-169 peptide vaccine.